PAR 1.82% 28.0¢ paradigm biopharmaceuticals limited..

Ann: PARADIGM REPORTS IND APPLICATION UPDATE, page-78

  1. 360 Posts.
    lightbulb Created with Sketch. 42
    well market now knows they have 60 days to wait for potential outcomes, its still a binary decision of yes/no so plenty of inherent risks and chance of further 60 days delay.
    Also market now knows only aussie trial will start this year, with patient recruitment in Q4, euro trial maybe starts in Q1 22 after sites identified and US trials starts...well anyones guess...
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.